BridgeBio Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BridgeBio Pharma, Inc.
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
US FDA, Foundation for the NIH, and NCI are considering a new PPP aimed at creating a repeatable process for development of drugs to treat ultra-rare cancers where commercial viability is lacking. Stakeholders say industry incentives, IP issues and reimbursement need attention.
The company presented detailed data for acoramidis at the ESC meeting over the weekend, though some data points like time to first CV hospitalization have not yet reported out.
BridgeBio and US FDA agreed on a path to accelerated approval for BB-418, a Phase III oral candidate for a subset of limb-girdle MD patients. If successful, it would bring BridgeBio’s third product to market.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Adrenas Therapeutics
- Aspa Therapeutics
- Audition Therapeutics
- Calcilytix Therapeutics
- CoA Therapeutics
- Fortify Therapeutics
- Origin Biosciences
- Phoenix Tissue Repair, Inc.
- QED Therapeutics
- Retinagenix LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.